Le Lézard
Classified in: Health
Subjects: MAT, IMA

SiliCycle inc. continues to build momentum in the cannabis market by obtaining authorization to sell medicinal products directly


QUEBEC, Jan. 11, 2022 /CNW Telbec/ - SiliCycle Inc., a company working in the health field, founded and established in Quebec, takes a major step allowing it to directly reach medical customers. The company has obtained approval to sell directly to consumers with a prescription for medical cannabis. It is through its subsidiary PurCann Pharma and under the OOVIE tm medical brand that the first products will be available on the Quebec and Canadian markets in the coming weeks.

Sale to consumers

SiliCycle, through its subsidiary PurCann Pharma, will market various products rich in CBD. Thanks to the unique expertise in extracting and purifying ingredients from natural biomasses and in fine chemicals developed over more than 26 years, the company transforms cannabis and hemp into purified and standardized extracts rich in CBD.

The products marketed under the OOVIE tm brand will primarily be intended for medical customers who have a prescription authorizing their purchase and consumption. OOVIE tm medical products will be composed of high-quality CBD extracts, highly pure, constant and standardized.

Products that hit the market over the next few weeks will be found in the form of CBD oils, sprays, creams and capsules. Users will therefore have access to standardized products at stable concentrations, without fluctuation in CBD content. An important step forward which meets the requirements of prescribing physicians.

Supplier of pharmaceutical companies

SiliCycle has been providing ingredients that go into a multitude of pharmaceuticals and drugs since its founding in 1995. The company has a reputation for providing products of the highest standard and of impeccable quality.

The company has chosen to invest in the cannabis market by taking advantage of this quality of production and high standards. Today, customers can be sure they are getting very high quality, consistent, and high purity products.

Facilities

It is in a state-of-the-art factory in the Technological Park of Metropolitan Quebec that the production of cannabis and hemp extracts takes place. Built in 2009 and expanded twice since, the plant occupies more than 45,000 square feet, including 9,000 square feet of laboratories and 20,000 square feet of manufacturing and packaging space - an investment totaling $ 45 million. The site is ISO 9001: 2015 certified. PurCann Pharma's dedicated space for operations has undergone further expansion in recent months to support the industry's rapid growth. The Good Production Practices (GPP) of Health Canada's Cannabis Regulations are implemented there, and the BPF (GMP) standards will be implemented in 2022-2023.

Quote

"We are all excited and proud to finally be able to deliver our products directly to consumers. Medical users can have confidence in our products which are of the highest quality according to pharmaceutical standards. SiliCycle has been active in the health and wellness industry for over 25 years and has respected the highest standards since its very beginnings.

Our ambition is to become a cannabis company that offers pharmaceutical grade products. We have a very high level of expertise and this market segment is currently unoccupied. Very few companies in the medical cannabis industry have pharmaceutical industry-recognized processes like we do. We are confident that users will see this difference. "

Hugo St-Laurent

About PurCann Pharma

PurCann Pharma is a subsidiary of the SiliCycle Group which specializes in the production and marketing of cannabinoid-rich extracts from hemp and cannabis grown in Canada. Purified and standardized extracts rich in CBD and/or THC are marketed in bulk or as finished products, such as tinctures, capsules, sprays, etc. PurCann Pharma also provides R&D, extraction, purification and packaging services.

About SiliCycle Inc.

SiliCycle, which is part of the SiliCycle Group, is a company that was founded in 1995 in Quebec. It is a world leader in the development, manufacturing and marketing of products for the pharmaceutical and life sciences industry. Technical expert in fine chemicals, SiliCycle sells its solutions in the extraction and purification of molecules of interest as well as in silica chemistry in over 105 countries.

Groupe SiliCycle's know-how is sought after by the major industrial manufacturers of pharmaceutical, cosmetic, nutraceutical, food companies as wells as analytical and chemical laboratories around the world. The members of the SiliCycle family are technology companies conducting research and development, manufacturing and targeting global markets with products and services dedicated to health, well-being and safeguarding the environment.

SOURCE SiliCycle inc


These press releases may also interest you

at 16:20
Summit Therapeutics Inc. ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 330,000 shares of common stock. Awards were made to six new employees of the Company. The...

at 16:15
eHealth, Inc. , a leading private online health insurance marketplace (the "Company"), today announced that on July 1, 2024, the Compensation Committee of its Board of Directors granted inducement stock unit awards to two new employees covering an...

at 16:10
bluebird bio, Inc. today announced that the Compensation Committee of the Company's Board of Directors approved an inducement grant of stock options to purchase a total of 300,000 shares of common stock to its chief financial officer, James...

at 16:10
The global consumer healthcare market size is estimated to grow by USD 170.2 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 6.78% during the forecast period. Awareness about lifestyle diseases is driving...

at 16:05
Voomtm Medical Devices, Inc. ("Voom"), the orthopedic medical device company behind the disruptive, game-changing Revcontm bunion screw technology, is honored to be named first on Podiatry Today's 2024 Top 10 Innovations list. Voom's one-of-a-kind...

at 16:05
Longboard Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the grant of inducement awards to four new employees. The Compensation...



News published on and distributed by: